INTRODUCTION
Epilepsy is typical in brain tumour patients, and its control plays imperative part in clinical management. Convulsions add up considerable morbidity in brain tumour patients [1] . Epilepsy in brain tumour patients are mostly symptomatic and localization associated, showing as either simple or complex seizures with/without secondary generalization.
A variety of factors influence epileptogenesis in brain tumour patients, namely tumour location and type, peritumoural environmental changes, and genetic factors. Hurdles of epilepsy medical treatment in brain tumour patients encompass the epilepsy refractoriness, which may be due to potential interactions of antiepileptic drugs (AEDs) as well as chemotherapeutic agents; multidrug-resistance proteins; and potential cognitive side-effects on utilization of AED besides prior damage to brain from radiotherapy or surgery [2, 3] . The brain tumour incidence in epilepsy patients is around 4 %. The seizure frequency is around 30 % or more in brain tumour patients, relying upon tumour type. Epilepsy is the major medical sign of tumour in nearly 30 -50 % of brain tumour patients; 10 -30 % of patients develop epilepsy during the tumour course [2-6].
There is a dearth of studies concerning seizures related to glioma. Our study objective was to elucidate outcomes of treatment and epidemiology of epilepsy related to glioma in a single center.
METHODS
This single center retrospective study was conducted at Department of Neurosurgery at Yichang Central People's hospital, China over the period, August 2009 to September 2015.
One hundred and nineteen successive patients having supratentorial gliomas in the Neurological Surgery Division of the hospital, in China, between August 2009 and September 2015 were included. Our study included 46 female and 73 male patients (average age: 57 years). All of the cases had pathologically confirmed diagnosis. Altogether, 98 astrocytic plus 21 oligodendroglial tumours were present. The summary of patient characteristics were mentioned in Table 1 . Since our center has no standard guidelines set for AED utilization, the particular AED used, relied upon preference of clinicians. Prophylactic AED treatment was customarily initiated prior to surgery. Phenytoin was typically chosen for the seizure prophylaxis during surgery. To accomplish stable concentration in serum, phenytoin was initiated 2 or 3 days prior to surgery and proceeded for 6 days post-surgery. In cases of adverse reactions to phenytoin and inadequately controlled seizures by phenytoin, patients were prescribed phenobarbital via intramuscular injection or suppository during surgery.
Post-surgery, all of the patients with WHOGrade III or Grade IV tumours were on treatment with irradiation along with temozolomide adjuvant concurrently, as per Stupp protocol [7] , while patients having Grade II tumours were on simple observation. Our study received Ethics Committee approval and confidentiality of patients was strictly maintained. Data were collected from medical records. The clinical as well as demographics variables obtained were noted below: age, sex, histology, seizure onset dates, AED usage, tumour location and seizure control etc.
Data analysis
Values are expressed as numbers and percentage. Fisher's exact and Chi square tests were used for analysis of difference in seizure incidence as per WHO Grades, histology, location as well as tumour number, age, and sex. Analysis of collected data was performed using SPSS v16.0 (SPSS Inc, Chicago, USA). P ≤ 0.05 was regarded as statistically significant.
RESULTS
Overall, 83 patients died by the time of final followup. Post-surgery median survival time for all of the patients was 20.2 months. The median follow up duration was noted to be 39.6 months (ranging from 3.7 -84.2 months) for 36 surviving patients.
Preoperative seizure incidence
In 29 (24.4 %) patients, the presenting symptom was seizure. No significant statistical difference in the seizure incidence as primary symptom, among patients having oligodendroglia tumours (40.9 %) vs. astrocytic tumours (22.7 %); (p = 0.145) was noted. Seizure incidence in patients, as per WHO grade were as follows: Grade II tumours 47.2 %; Grade III tumours 28.4 %; and Grade IV tumours 19.6 %. The seizure incidence was significantly higher in patients having Grade II tumours than patients having Grade IV tumours (p = 0.026). Seizures were seen most commonly in younger (< 50 yrs, 54.1 %) than older patients (≥ 50 yr, p < 0.001). Non-significant inclination for frontal lobe tumours to exhibit more frequent onset of seizures than the tumours present in other regions (p = 0.095). The clinical/ demographic characteristics are presented in Table 1 . The seizure incidence as primary symptom and pertinent characteristics of patients are presented in Table 2 .
Besides 29 patients, whose presenting symptom was seizures, additional 10 patients (8.4 %) developed seizures in between their first visit and surgery. AED was given quickly post one seizure had happened in all the patients having seizures. Phenytoin was the widely utilized AED (48.2 %), however physicians likewise as often as possible chose valproic acid (24.1 %) and phenobarbital (20.7 %).
Out of 80 patients with no seizures, 49 patients were given AED prophylactically prior to surgery. Phenytoin was the most widely utilized AED (36.8 %) for the prophylactic use; however, physicians likewise as often as possible chose phenobarbital (11.6 %) and valproic acid (7.8 %). 
Seizures amid early post-operative phase
During surgery, all the patients were given AED prophylactically. Most of the patients received phenytoin (85.7 %). The rest were given Phenobarbital (intramuscular injection/supposetory; 11.8 %), oral valproic acid (1.6 %), and zonisamide (0.8 %). Ten patients (8.4 %) developed seizures amid initial postoperative week. Patients with seizure history prior to surgery experienced higher risk (17.2 %) than that of others significantly (5.2 %, p = 0.045). The seizures happened more often during surgery day (36.9 %). The seizure incidence seen in phenobarbital-treated patients (21.4 %) was greater than patients on phenytoin (6.9%); there was no statistically significant difference (p = 0.266).
Seizures amid follow up
By the last follow up period, 73 (61.3 %) patients developed seizures. Seizures were seen most commonly in younger (< 50 yrs, 84.1 %) than older patients (≥ 50 yrs, 52.6 %, p < 0.003). The main region with significant association with greater seizure incidence was frontal lobe (p = 0.035). Overall seizure incidence and pertinent characteristics of patients are presented in Table  3 . Out of 80 patients with none of the preoperative seizures, 15 patients withdrew AED by the first post-operative week whereas the rest of 65 patients were given AED on a more extended period. Time to first seizure post-surgery as per prophylactic AED duration is depicted in Figure  1 . No significant time difference to first seizure postsurgery with/ without AED prophylaxis after 1 week post-surgery among patients with no preoperative seizure history was noted (log rank p = 0.584). AED continuation beyond first postoperative week granted no added benefit. Besides 15 patients, who discontinued AED, 39 additional patients discontinued later. Out of those 54 patients, 14 developed epileptic seizures within 6 months and again needed AED. The rest of 40 patients experienced no seizures and hence got none of the AEDs amid followup period (median, 7.2 months; range, 1.4 -69.1 months).
DISCUSSION
Primary brain tumours have greater seizure incidence than metastatic tumours [8] . In the present study, around 65 % of the patients having supratentorial gliomas developed epilepsy. It was recently reported that glutamate released via glioma cells might be a potential cause of seizures in glioma patients [9] . Despite the fact that the exact way is unclear regarding epileptogenesis, tumours close to cortex and gradually progressive tumours accounted for higher seizure incidence [10] . In the present study, patients having oligodendroglia tumours (that habitually penetrate the cortex), had a high seizure incidence than that of astrocytic tumours. Also, the patients with the low grade tumours additionally demonstrated high seizure incidence. This information show that the patients who are relied upon for longer survival have a greater seizure risk. In this manner, seizure control is a central point in keeping up quality of life of patients having glioma.
Recently, researchers revealed an exceedingly low seizure incidence amid craniotomy without AEDs [11, 12] . Lwu et al demonstrated 3 % of patients experiencing seizures during perioperative period with none of the AEDs, while noting no seizures on AED prophylaxis [11] . This may be an underestimate of seizure incidence as they included only the patients having malignant glioma and no seizure history. Nonetheless, it is critical to take into account the need for AEDs in perioperative seizure prophylaxis from cost and benefit point of view. Contrary to the above report, in this study, 8.4 % developed seizures in first week post craniotomy, despite the fact that all patients got prophylactic AEDs. Nearly 5.2 % of patients with malignant tumours and no seizure history developed perioperative seizures. The greater perioperative seizure incidence in the patients on prophylactic AED compared to what was noted in Lwu et al study patients who were on no prophylaxis brings up issue of justified prophylactic utilization of AED in perioperative seizure control. Randomized trials are needed to elucidate if AEDs are fundamental in perioperative seizures prophylaxis in case of patients with no seizure history. On the other hand, there is supposedly a high seizure incidence amid awake craniotomy [13] . Besides, seizures amid awake surgery might interfere with neurological function monitoring [14] . Though fact that the seizure incidence might be low amid craniotomy, it is likely prophylactic AEDs are prescribed in surgeries of that type.
In the present study, phenytoin was the widely utilized drug in perioperative seizure prophylaxis. Lately, researchers have demonstrated levetiracetam to be effective in seizure prophylaxis amid and not long after craniotomy [15] . Besides, levetiracetam is allegedly better than phenytoin for seizure prophylaxis during surgery [16] .
In the event that seizures were very much in control amid surgery, we proceeded with the same AED in postoperative seizure prophylaxis in many patients. In this way, phenytoin was the most widely utilized AED postoperatively. However, phenytoin was very poorly tolerated and as a result, needed withdrawal within 2 months in greater than half of the patients. More regular reasons for withdrawal were adverse effects (rash, liver dysfunction) than unsatisfactory control of seizures.
Rash and dizziness were the most common reasons for carbamazepine withdrawal. Also, a few patients were on this agent due to poor acceptability. Levetiracetam acceptability was noted to be excellent with satisfactory seizure control and adverse events of lesser frequency. Although, significantly more number of psychiatric or behavioral adverse events were reported to be caused by levetiracetam than by gabapentin or lamotrigine [17] . Fortunately, none of the patients experienced the above kinds of adverse effects and in any case, it is important to be aware of such effects while utilizing levetiracetam for seizure control.
In spite of the fact of secure withdrawal of AEDs in 39/119 patients (32.8 %), more than two AEDs were needed for seizure control in 34/119 patients (28.6 %). These outcomes show how troublesome the seizure control can be in glioma patients. Additionally, during treatment, it is critical to watch out for interactions amongst AEDs and different drugs utilized for brain tumour treatment. The majority of the already accessible AEDs are metabolized by means of the cytochrome P450 pathway. Some AEDs influence the action of that enzyme. For instance, valproic acid inhibits CYP 2C19 whereas phenytoin and phenobarbital induces CYP 3A4 [18] . Then again, a significant number of the agents that are often used for brain tumour treatment are additionally metabolized via this pathway and might likewise influence it. CYP 3A4 induction by dexamethasone [19] and its reduction by cimetidine [20] are well known. Also, valproic acid inhibits glucuronidation while carbamazepine, phenytoin and phenobarbital induce it. Unstable AED concentrations due to such interactions leads to unsatisfactory seizure control. It is vital to consider adverse event risk or activity reduction of anti-cancer drugs due to metabolic interactions amongst AEDs and anticancer agents. Levetiracetam and gabapentin are not metabolized and are generally discharged by the kidneys. Hence they do not have much interaction with other therapeutic agents and are therefore safer to use with other anticancer drugs.
Klein et al earlier revealed that patients having glioma demonstrate poor cognitive function when compared to healthy controls. It was also described that treatment with AEDs, as opposed to seizure recurrence, negatively influences cognitive function [21] . To prevent AED adverse effects, along with deterioration of cognition, the American Academy of Neurology Quality Standards Subcommittee has developed guidelines which prescribe tapering and discontinuation of AED beyond the first postoperative week in the patients having no seizure history [22] . In the present study, AED continuation beyond 1 week post craniotomy in the patients with no seizure history did not prevent postoperative seizure onset. In this way, our outcomes reinforce the above mentioned guidelines in regards to AED prophylaxis for the patients with no prior seizures. Nevertheless, it is crucial to take account that no seizures prior to craniotomy does not ensure no seizure course post-surgery. In the present study, greater than 40 % of the patients with no seizure prior to surgery experienced the seizures post-surgery, despite on AEDs.
Epilepsy in brain tumour patients is a distinctive form where the seizure risk might change as per tumour status. Recurrence of tumour and alterations in encompassing brain tissue due to therapy, for example, necrosis post radiation treatment, might change the seizure risk. Hence, medication discontinuation should be examined carefully, despite the fact that these drugs can lead to decreased cognitive function. Newer AEDs, namely levetiracetam, gabapentin and lamotrigine on the other hand, are apparently safe with respect to the cognitive function [23] . Levetiracetam, apparently enhances memories in the animal models [24] and enhances quality of life in brain tumour patients having epilepsy [25] . Of late, verbal memory improvement in highgrade glioma patients on levetiracetam has been demonstrated [26] . We prescribe picking this AED in patients where AED discontinuation is not advisable due to unsteady conditions of tumour.
Limitations of the study
Certain innate limitations need consideration during results interpretation of of present study. This single-center study has limited number of patients, hence the results generalization should be done with great care. We were not able to assess all variables and were limited by the treating physicians in regards to completeness of data or proper documentation. Limited data was captured.
CONCLUSION
Effective prophylaxis of seizure and acceptable adverse event profile should be considered significant in AEDs selection. Additionally, in brain tumour patients suffering epilepsy, it is important to consider drug interactions with other therapeutic agents and cognitive impairment risk. The lower cognitive impairment risk and the renal discharge associated with newer AEDs make them more suitable than the older therapeutic agents for epilepsy control in brain tumour patients.
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